US Pharma MarketingThe post Roche to acquire PathAI in $1.05bn deal appeared first on Medical Device Network.
Roche to acquire PathAI in $1.05bn deal
Roche has signed a definitive merger agreement for the acquisition of US-based PathAI in a deal valued at up to $1.05bn. Upon completion, expected in the second half of the year, PathAI will join Roche's diagnostics division. The acquisition aims to reinforce Roche’s digital pathology position. Credit: Jonathan Weiss / Shutterstock.com. Roche has signed a definitive merger agreement for the acquisition of US-based PathAI in a deal valued at up to $1.05bn. PathAI specialises in digital pathology and AI-powered diagnostics, serving pathology laboratories and the biopharma industry. Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading…
Roche has signed a definitive merger agreement for the acquisition of US-based PathAI in a deal valued at up to $1.05bn.
Source: Medical Device Network